Table 4.
Differences in clinical features between Ang2low and Ang2high patients treated with curative ablation therapy
| Characteristics | Ang2low (<3.5 ng/mL, n=67) | Ang2high (≥3.5 ng/mL, n=39) | p-value |
|---|---|---|---|
| Age (years)* | 70 (40-88) | 73 (50-87) | 0.467 |
| Sex (male/female) | 49/18 | 21/18 | 0.070 |
| Etiology HBV/HCV/others | 6/50/11 | 4/24/11 | 0.317 |
| Liver damage (CH/LC) | 17/50 | 3/36 | 0.047 |
| Child-Pugh classification (A/B/C) | 63/4/0 | 33/5/1 | 0.190 |
| Fib-4 index* | 5.17 (1.19-19.91) | 6.28 (2.39-15.69) | 0.013 |
| AFP (ng/mL)* | 8.6 (1.8-1,377.5) | 15.2 (2.6-220.4) | 0.075 |
| DCP (mAU/mL)* | 28 (11-17,588) | 36 (14-3,785) | 0.138 |
| Ang2 (ng/mL)* | 2.33 (1.26-3.47) | 4.83 (3.52-11.08) | <0.001 |
| Tumor numbers (solitary/multiple) | 52/15 | 28/11 | 0.662 |
| Maximal tumor diameter (≤20/>20 mm) | 46/21 | 24/15 | 0.594 |
| UICC stage (I/II) | 52/15 | 28/11 | 0.662 |
*Median (range).